# Kramer Capital Partners

> Kramer Capital Partners is a VC fund in Stamford backing Medical and Health Care. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Stamford, United States
- Total investments: 3
- Last investment: Dec 2012
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://kramercap.com

Kramer Capital Partners is a venture capital company based in Stamford, Connecticut.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 33% |
| Health Care | 1 | 33% |
| Biotechnology | 1 | 33% |
| Health Diagnostics | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 33% |
| Series B | 1 | 33% |
| Series C | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Knopp Biosciences | Knopp Biosciences is a drug discovery and development company that focuses on delivering breakthrough treatments in neurological disorders through innovation, experience, and partnership. The company targets diseases imposing high costs on the healthcare system, with patient populations clearly identifiable using validated biomarkers or genetictesting. The company's goal is to accelerate and advance treatment, change the course of diseases, and improve the lives of the patients and their families.Knopp Biosciences was founded in 2004 and is headquartered in Pittsburgh, Pennsylvania. | $30M | Series C | Dec 03, 2012 |  |
| Knopp Biosciences | Knopp Biosciences is a drug discovery and development company that focuses on delivering breakthrough treatments in neurological disorders through innovation, experience, and partnership. The company targets diseases imposing high costs on the healthcare system, with patient populations clearly identifiable using validated biomarkers or genetictesting. The company's goal is to accelerate and advance treatment, change the course of diseases, and improve the lives of the patients and their families.Knopp Biosciences was founded in 2004 and is headquartered in Pittsburgh, Pennsylvania. | $10M | Series B | Jan 22, 2008 |  |
| Knopp Biosciences | Knopp Biosciences is a drug discovery and development company that focuses on delivering breakthrough treatments in neurological disorders through innovation, experience, and partnership. The company targets diseases imposing high costs on the healthcare system, with patient populations clearly identifiable using validated biomarkers or genetictesting. The company's goal is to accelerate and advance treatment, change the course of diseases, and improve the lives of the patients and their families.Knopp Biosciences was founded in 2004 and is headquartered in Pittsburgh, Pennsylvania. | $10M | Series A | Jan 01, 2006 |  |

3 of 3 investments shown.

## Co-investors
- LaunchCyte — VC Fund, 3 deals together
- [Saturn Partners](https://shizune.co/investors/profile/saturn-venture-partners) — VC Fund, 3 deals together
- [Biogen](https://shizune.co/investors/profile/biogen-idec) — VC Fund, 1 deal together
- [Innovation Works](https://shizune.co/investors/profile/innovation-works) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Kramer Capital Partners invest in?

Kramer Capital Partners invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Kramer Capital Partners last invest?

The most recent investment recorded for Kramer Capital Partners closed in Dec 2012. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co